中源协和 (600645)

VCANBIO Cell and Gene Engineering Corp., Ltd.

ASH

Tags

SSE 580 IndexLong-Term Non-Dividend PayersImmunotherapyInnovative DrugsDebt Resolution AMCPharmaceutical ManufacturingPharmaceuticals and HealthcareGene ConceptBiological ProductsHepatitis ConceptMargin Trading and Securities LendingAssisted Reproduction

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 46794.89
  • Circulating A-Shares(W): 46777.02
  • Earnings Per Share(RMB): 0.2400
  • Net Assets Per Share(RMB): 7.9307
  • Operating Revenue(W RMB): 109246.02
  • Total Profit(W RMB): 13890.19
  • **Net Profit Attributable to Parent(W RMB) **: 10790.68
  • Net Profit Growth Rate(%): -19.18
  • Weighted Return on Equity(%): 2.9600
  • Operating Cash Flow Per Share(RMB): 0.4760
  • Undistributed Profit Per Share(RMB): -0.2333
  • Capital Reserve Per Share(RMB): 7.2442

2. Main Business

The main business covers:

  • Cell detection, preparation, and storage
  • Genetic testing
  • R&D, production, and sales of in vitro diagnostic reagents and instruments
  • R&D, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and laboratory reagents

3. Company Basic Information

  • Company Name: Zhongyuan Union Cell & Gene Engineering Co., Ltd.
  • Listing Date: 1993-05-04
  • Industry: Pharmaceutical Manufacturing
  • Address: Registered Address: Room 2, Building A, No. 12 Meiyuan Road, Huayuan Industrial Park, Binhai High-tech Zone, Tianjin; Office Address: No. 12 Meiyuan Road, Huayuan Industrial Park, Nankai District, Tianjin
  • Website: https://www.vcanbio.com
  • Company Profile: The company was jointly established in 1992 by three institutions including Shanghai Universe Velvet Factory. Initially, the collective assets of the promoters were converted into 1.8221 million promoter shares with a face value of RMB 10. After the initial public offering from August to October of the same year, the total shares reached 3.0221 million. At the time of listing, the shares were split into 30.221 million shares with a face value of RMB 1 per share. Its 2 million internal employee shares were listed for trading on April 19, 1994. The 1996 profit distribution plan has been approved by the shareholders' meeting.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Tianjin Deyuan Health Management Co., Ltd. General Legal Person 5678.75 12.14
2 Shenzhen Jiadao Success Investment Enterprise (Limited Partnership) General Legal Person 4494.38 9.61
3 Hong Kong Securities Clearing Company Ltd. Northbound Capital 1525.00 3.26
4 Huabao CSI Medical ETF Fund 1056.88 2.26
5 Beijing Yinhong Chunhui Investment Management Co., Ltd. General Legal Person 576.13 1.23
6 Southern CSI 1000 ETF Fund 342.03 0.73
7 Galaxy Medicine & Health Mixed Securities Investment Fund - Class A Fund 106.99 0.23
8 Mingya CSI 1000 Index Enhanced Securities Investment Fund - Class A Fund 2.51 0.01

5. Concept Sectors

  • Gene Concept
  • Immunotherapy
  • Assisted Reproduction
  • Hepatitis Concept
  • Innovative Drugs
  • Margin Trading & Securities Lending
  • Debt-to-Asset Management Companies (AMC)
  • Long-Term No Dividend

Remarks

  • Data update date: 2025-10-30
  • Data source: Public Market Information